Bristol-Myers Squibb Overview
- Founded
-
1887
- Status
-
Public
- Employees
-
32,200
- Stock Symbol
-
BMY
- Investments
-
106
- Share Price
-
$74.45
- (As of Friday Closing)
Bristol-Myers Squibb General Information
Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Stock Exchange
NYS
Primary Office
- 430 East 29th Street
- 14th Floor
- New York, NY 10016
- United States
Bristol-Myers Squibb Timeline
Bristol-Myers Squibb Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $74.45 | $72.77 | $62.90 - $81.44 | $155B | 2.13B | 9M | $2.97 |
Bristol-Myers Squibb Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 184,123,237 | 184,123,237 | 168,486,862 | 164,770,387 |
| Revenue | 46,159,000 | 46,159,000 | 46,385,000 | 42,518,000 |
| EBITDA | 18,540,000 | 18,540,000 | 20,191,000 | 5,035,000 |
| Net Income | 6,327,000 | 6,327,000 | 6,994,000 | (9,015,000) |
| Total Assets | 109,314,000 | 118,481,000 | ||
| Total Debt | 0 | 0 | 45,596,000 | 51,673,000 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Bristol-Myers Squibb Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bristol-Myers Squibb Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cance
Drug Discovery
New York, NY
32,200
As of 2021
00000
00000000000
00000
000000
ercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute ir
0000000000000
Cambridge, MA
0000
As of 0000
000.00
000
0000-00-00
000000&0
000000
dunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exe
000000000000000
Foster City, CA
00000
As of 0000
00.000
000000000
00.000
Add Comparison
Bristol-Myers Squibb Competitors (11)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biogen | Formerly VC-backed | Cambridge, MA | 0000 | 000.00 | 000000&0 | |
| 000000 00000000 | Formerly VC-backed | Foster City, CA | 00000 | 00.000 | 000000000 | 00.000 |
| 000000 | Corporation | Durham, NC | 00 | 000.00 | 000000000 | 000.00 |
| 0000000 0000000000 | Formerly VC-backed | Redwood City, CA | 000 | 00000 | 000000000 | 00000 |
| 000000 | Corporation | Paris, France | 00000 | 000000000000 |
Bristol-Myers Squibb Patents
Bristol-Myers Squibb Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2022033757-A | Compositions and methods for treating tauopathies | Inactive | 10-Nov-2021 | ||
| US-20220388987-A1 | Substituted heterocyclic compounds | Pending | 14-May-2021 | 0000000000 | |
| US-20220411384-A1 | Substituted heterocyclic compounds | Pending | 14-May-2021 | 0000000000 | |
| US-20220362255-A1 | Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione | Pending | 21-Apr-2021 | 00000000000 | |
| US-20220324840-A1 | Pyridinyl substituted oxoisoindoline compounds | Pending | 06-Apr-2021 | C07D401/14 |
Bristol-Myers Squibb Executive Team (64)
Bristol-Myers Squibb Board Members (20)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000000 0000 | Self | Board Member | 000 0000 |
| 000000 000000 00 | Self | Board Member | 000 0000 |
| 00000000 0000000 0 | Bristol-Myers Squibb | Chairman & Chief Executive Officer | 000 0000 |
| 00000 000000 00 | Self | Board Member | 000 0000 |
| 00000 0000000 00.0 | Bristol-Myers Squibb | Board Member, Senior Group Leader, The Francis Crick Institute and Chief Scientist, Cancer Research UK | 000 0000 |
Bristol-Myers Squibb Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Bristol-Myers Squibb Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Bristol-Myers Squibb Investments & Acquisitions (106)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 | 26-Jan-2023 | 00000 0000 | 000.00 | Discovery Tools (Healthcare) | |
| 00000000 000 | 05-Jan-2023 | 000000000 | 0000 | Buildings and Property | |
| 0000000000 | 20-Dec-2022 | 00000 0000 | 00000 | Drug Discovery | |
| 00000 0000000 | 29-Nov-2022 | 00000 0000 | 000.00 | Drug Discovery | |
| SyntheX | 04-Oct-2022 | Later Stage VC | Drug Discovery |
Bristol-Myers Squibb Subsidiaries (8)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| IFM Therapeutics | Drug Discovery | Boston, MA | 2015 |
| 0000000 00000 0000 | Drug Discovery | San Diego, CA | 0000 |
| 000000000 | Drug Discovery | Brisbane, CA | 0000 |
| 0000000 | Biotechnology | Austin, TX | 0000 |
| 0000000-00000 0000 | Foundation | New York, NY | 0000 |
Bristol-Myers Squibb ESG
Risk Overview
Risk Rating
Updated August, 13, 2022
22.73 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 1,008
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 465
Rank
0.0
Percentile
Bristol-Myers Squibb Exits (30)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000000000 | 20-Jun-2021 | 00000 00000 00 | 00000 | Completed |
|
| 0000000000 | 03-Mar-2021 | 00000 00000 00 | 00000 | Completed |
|
| 00000 00000000 | 05-Jan-2021 | 00000 00000 00 | 00000 | Completed |
|
| 000000 00000000000 | 29-May-2020 | 00000 00000 00 | 0000 | Completed |
|
| Silverback Therapeutics | 11-Mar-2020 | Early Stage VC | 000.00 | Completed |
|